Dato-DXd Deemed New Treatment Option for HR+, HER2- Advanced Breast Cancer

Dato-DXd improved outcomes over chemotherapy in a phase 3 trial of patients with previously treated, inoperable or metastatic, HR+, HER2- breast cancer. Dato-DXd improved outcomes over chemotherapy in a phase 3 trial of patients with previously treated, inoperable or metastatic, HR+, HER2- breast cancer.

Related Keywords

San Antonio ,Texas ,United States ,Massachusetts ,Boston ,Aditya Bardia , ,San Antonio Breast Cancer Symposium ,Massachusetts General Hospital ,